Product Information

MOEXIPRIL HCL 7.5 MG TABLET is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.9011 per EA under NDC 68462020901. Its NADAC has been published 656 times since Nov 28, 2013.

FDA first approved this application on Mar 30, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

MOEXIPRIL HCL 7.5 MG TABLET

Moexipril Hydrochloride
$0.9011per EA

Strength

7.5 mg/1

NDC

68462020901

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

10/21/2026

Active Ingredients

MOEXIPRIL HYDROCHLORIDE

Approval Type

Generic (ANDA)

FDA Application

ANDA090416

FDA Approved

3/30/2010

TE Code

AB

On Market Since

12/31/2010

Pharmacological Classes

Angiotensin Converting Enzyme Inhibitor
Angiotensin-converting Enzyme Inhibitors

Price Statistics

The NADAC for MOEXIPRIL HCL 7.5 MG TABLET has been published 656 times since Nov 28, 2013, and over the history we have for it it has risen 201.8%. The table below summarizes its recorded NADAC range and movement.

Current price$0.9011 per EA
All-time high$0.9671 (Apr 15, 2026)
All-time low$0.2985 (Nov 28, 2013)
52-week high$0.9671
52-week low$0.8877
Median price$0.7553
Average price$0.7754
Largest weekly change+76.0% (Dec 18, 2013)
Weeks tracked656
Tracking sinceNov 28, 2013

Price History

1W

0.0%

1M

+0.4%

3M

+0.8%

6M

+1.5%

1Y

-6.3%

3Y

+0.9%

5Y

+19.3%

All

+201.8%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of MOEXIPRIL HCL 7.5 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for MOEXIPRIL HCL 7.5 MG TABLET, manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.9011 per EA (NDC 68462020901), effective Nov 18, 2026.

How has the price of MOEXIPRIL HCL 7.5 MG TABLET changed over time?

Over the history we have for it, the NADAC for MOEXIPRIL HCL 7.5 MG TABLET has risen 201.8%. It has been tracked across 656 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for MOEXIPRIL HCL 7.5 MG TABLET?

Since Nov 28, 2013, the NADAC for MOEXIPRIL HCL 7.5 MG TABLET has ranged from a low of $0.2985 (Nov 28, 2013) to a high of $0.9671 (Apr 15, 2026), with a median of $0.7553 per EA.

Are there cheaper alternatives to MOEXIPRIL HCL 7.5 MG TABLET?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as MOEXIPRIL HCL 7.5 MG TABLET in a comparable dosage form, but none are currently priced below it.

Who manufactures MOEXIPRIL HCL 7.5 MG TABLET?

MOEXIPRIL HCL 7.5 MG TABLET (NDC 68462020901) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.